KATIA RAMOS MOREIRA LEITE
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cirurgia, Faculdade de Medicina - Docente
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental, Hospital das Clínicas, Faculdade de Medicina
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
- Involvement of the central nervous system in neuroblastomas: A potential direct pathway(2020) ODONE-FILHO, Vicente; CRISTOFANI, Lilian Maria; MALUF, Paulo Taufi; ALMEIDA, Maria Tereza Assis; HALLEY, Nathalia; VINCE, Carolina Sgarioni Camargo; AZAMBUJA, Alessandra Milani Prandini de; BRUMATTI, Melina; LUBRAICO, Priscilla; LOPES, Luiz Heraldo Arouche da Camara; LEITE, Katia Ramos Moreira; SILVA, Joao Luis Fernandes; PLESE, Jose Pindaro Pereira; WELTMAN, EduardoAlthough frequently disseminated to other anatomical sites, neuroblastoma (NB) is rarely reported as involving the central nervous system (CNS), which may reflect insufficient research in poorly controlled systemic disease. Here we demonstrate the involvement of the CNS in patients with NB over 18 months of age at diagnosis of extensive systemic disease. Meningeal metastases were observed even in the presence of complete systemic control. Although no improvement in patient's survival was observed, radiotherapy was effective in preventing CNS recurrence after observation of actual or previous dural disease. In conclusion, this study uncovered the uncommon pathologic involvement of the CNS in children with advanced NB and underscores the meningeal surface as a potential pathway for this to occur.
conferenceObject DO THE REGULATION OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES HAVE ANY ASSOCIATION WITH PEYRONIE'S DISEASE?(2020) NETO, Cristovao Barbosa; REIS, Sabrina T.; ARANTES, Gabriel; NASCIMENTO, Bruno; SAYAO, Rogerio; LEITE, Katia Ramos; SROUGI, Miguel; NAHAS, William; CURY, Jose- Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study(2020) STROM, Peter; KARTASALO, Kimmo; OLSSON, Henrik; SOLORZANO, Leslie; DELAHUNT, Brett; BERNEY, Daniel M.; BOSTWICK, David G.; EVANS, Andrew J.; GRIGNON, David J.; HUMPHREY, Peter A.; ICZKOWSKI, Kenneth A.; KENCH, James G.; KRISTIANSEN, Glen; KWAST, Theodorus H. van der; LEITE, Katia R. M.; MCKENNEY, Jesse K.; OXLEY, Jon; PAN, Chin-Chen; SAMARATUNGA, Hemamali; SRIGLEY, John R.; TAKAHASHI, Hiroyuki; TSUZUKI, Toyonori; VARMA, Murali; ZHOU, Ming; LINDBERG, Johan; LINDSKOG, Cecilia; RUUSUVUORI, Pekka; WAHLBY, Carolina; GRONBERG, Henrik; RANTALAINEN, Mattias; EGEVAD, Lars; EKLUND, MartinBackground An increasing volume of prostate biopsies and a worldwide shortage of urological pathologists puts a strain on pathology departments. Additionally, the high intra-observer and inter-observer variability in grading can result in overtreatment and undertreatment of prostate cancer. To alleviate these problems, we aimed to develop an artificial intelligence (AI) system with clinically acceptable accuracy for prostate cancer detection, localisation, and Gleason grading. Methods We digitised 6682 slides from needle core biopsies from 976 randomly selected participants aged 50-69 in the Swedish prospective and population-based STHLM3 diagnostic study done between May 28,2012, and Dec 30,2014 (ISRCTN84445406), and another 271 from 93 men from outside the study. The resulting images were used to train deep neural networks for assessment of prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test dataset comprising 1631 biopsies from 246 men from STHLM3 and an external validation dataset of 330 biopsies from 73 men. We also evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics and tumour extent predictions by correlating predicted cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI system and the expert urological pathologists using Cohen's kappa. Findings The AI achieved an area under the receiver operating characteristics curve of 0.997 (95% CI 0.994-0.999) for distinguishing between benign (n=910) and malignant (n=721) biopsy cores on the independent test dataset and 0.986 (0.972-0.996) on the external validation dataset (benign n=108, malignant n=222). The correlation between cancer length predicted by the AI and assigned by the reporting pathologist was 0.96 (95% CI 0.95-0.97) for the independent test dataset and 0.87 (0.84-0.90) for the external validation dataset. For assigning Gleason grades, the AI achieved a mean pairwise kappa of 0.62, which was within the range of the corresponding values for the expert pathologists (0.60-0.73). Interpretation An AI system can be trained to detect and grade cancer in prostate needle biopsy samples at a ranking comparable to that of international experts in prostate pathology. Clinical application could reduce pathology workload by reducing the assessment of benign biopsies and by automating the task of measuring cancer length in positive biopsy cores. An AI system with expert-level grading performance might contribute a second opinion, aid in standardising grading, and provide pathology expertise in parts of the world where it does not exist.
- Nomograms using a small panel of genes for predicting the diagnosis and aggressiveness of prostate cancer(2020) LEITE, Katia R. M.; ORTEGA, Fabio L.; DAMIANI, Lucas P.; GUIMARAES, Vanessa; VIANA, Nayara; SILVA, Iran A.; REIS, Sabrina T.; PIMENTA, Ruan; ADONIAS, Sanarelly P.; CHAMMAS, Cristina; SROUGI, Miguel; NAHAS, Willian
- Is prostate infarction and acute urinary retention a possible complication of severe COVID-19 infection?(2020) DUARTE, Sergio A. C.; PEREIRA, Jessica G.; ISCAIFE, Alexandre; LEITE, Katia R. M.; ANTUNES, Alberto A.
- Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer(2020) FERREIRA, Janaina Mendes; DELLE, Humberto; CAMACHO, Cleber Pinto; ALMEIDA, Robson Jose; REIS, Sabrina Thalita; MATOS, Yves Silva Teles; LIMA, Amanda M. Ramos; LEITE, Katia Ramos Moreira; PONTES-JUNIOR, Jose; SROUGI, MiguelBackground Indoleamine 2,3-dioxygenase (IDO1) is an enzyme that acts as an immunomodulatory molecule. It is found in several types of cancer where it seems to be associated with tumor escape due to its immunosuppressive mechanisms. However, the role of IDO1 expression in prostate cancer (PC) is unclear. The aim of our study was to evaluate the expression of IDO1 in localized PC and to correlate with the classic prognostic factor and recurrence after surgical treatment. Methods We retrospectively evaluated surgical specimens from 111 patients with localized PC, who underwent radical prostatectomy. Recurrence was defined as a prostate specific antigen (PSA) level exceeding 0.2 ng/mL postoperatively, and the follow-up was 123 months. IDO1 expression was evaluated by immunohistochemistry in 72 cases of which 42 (58%) had biochemical recurrence. Results Lower IDO1 expression was associated with higher Gleason score (p = 0.022) and PSA levels (p = 0.042). The multivariate analyses revealed that the loss of IDO1 and higher PSA were independently associated with biochemical recurrence. The chance of recurrence was increased by 85% in patients with lower IDO1 [OR = 0.15;p = 0.009 CI 95% (0.038-0.633)] and increased by 5.5 times in patients with higher PSA [OR = 5.51;p = 0.012 CI 95% (1.435-21.21)]. The recurrence-free survival curve also demonstrates that lower IDO1 was associated with lower time to biochemical recurrence (p = 0.0004). Conclusion The loss of IDO1 expression was associated with increased chance of biochemical recurrence, higher PSA, and a Gleason score in localized PC.
- Granular necrosis: a distinctive form of cell death in malignant tumours(2020) SAMARATUNGA, Hemamali; DELAHUNT, Brett; SRIGLEY, John R.; BERNEY, Daniel M.; CHENG, Liang; EVANS, Andrew; FURUSAT, Bungo; LEITE, Katia R. M.; MACLENNAN, Gregory T.; MARTIGNONI, Guido; MOCH, Holger; PAN, Chin-Chen; PANER, Gladell; RO, Jae; THUNDERS, Michelle; TSUZUKI, Toyonori; WHEELER, Thomas; KWAST, Theodorus van der; VARMA, Murali; WILLIAMSON, Sean R.; YAXLEY, John W.; EGEVAD, LarsFoci of necrosis are frequently seen in malignant tumours and may be due to a variety of causes. Different types of necrosis are given various names based upon their morphological features and presumed pathogenesis, such as coagulative, liquefactive and fibrinoid necrosis. Here, we propose the term 'granular necrosis' (GN) for a specific form of tumour necrosis characterised by the presence of well-defined necrotic foci being sharply demarcated from adjacent viable tumour. A constant feature is loss of ar-chitecture resulting in an amorphous necrotic mass containing granular nuclear and cytoplasmic debris, without an associated neutrophilic infiltrate. There is usu-ally extensive karyorrhexis, which in larger tumours is more prominent at the periphery. These foci are often microscopic but may range up to several millimetres or larger in size. This distinctive form of necrosis has been erroneously given a variety of names in the literature including coagulative necrosis and microscopic necrosis, which on the basis of the aforementioned gross and microscopic findings is inappropriate. It is apparent that this is a specific form of necrosis, hence the descriptive term 'granular necrosis' that differentiates this form of ne-crosis from other types. The presence of GN is recognised as occurring in a variety of tumour types, being commonly seen in renal cell carcinoma, where it has been shown to have independent prognostic significance. In some epithelial and stromal tumours of the uterus, the presence of GN also has prognostic significance and is a defining feature for the differentiation of uterine leiomyoma and leiomyosarcoma. The pathogenesis of GN is unresolved. It does not show the features of apoptosis and in recent studies has been shown to have some of the molecular changes associated with necroptosis.
- Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded(2020) SAMARATUNGA, Hemamali; DELAHUNT, Brett; EGEVAD, Lars; SRIGLEY, John R.; BILLIS, Athanase; BOSTWICK, David G.; CAMPARO, Philippe; CHENG, Liang; CLOUSTON, David; DENHAM, James; FURUSATO, Bungo; HARTMANN, Arndt; JUFE, Laura; KENCH, James; KENWRIGHT, Diane N.; KRISTIANSEN, Glen; LEITE, Katia R. M.; MACLENNAN, Gregory T.; MERRIMEN, Jennifer; MOCH, Holger; OXLEY, Jon; PAN, Chin-Chen; PANER, Gladell; RO, Jae; SESTERHENN, Isabell A. M.; SHANKS, Jonathan; THUNDERS, Michelle; TSUZUKI, Toyonori; WHEELER, Thomas; YAXLEY, John W.; VARMA, MuraliInfiltration of the prostatic ducts by prostatic adenocarcinoma occurs relatively frequently, being most commonly associated with high grade disease. It is now recognised that intraductal carcinoma of the prostate (IDCP) has an associated poor prognosis and this is reflected in its histological, molecular and immunohistochemical features. The current recommendation of the World Health Organization is that IDCP not be taken into consideration when grading prostate adenocarcinoma. It is apparent that Gleason did not differentiate between IDCP and stromal invasive carcinoma when developing and validating his grading system, and recent studies suggest that the incorporation of IDCP grading into the overall grading of the specimen provides additional prognostic information.
- Digital application developed to evaluate functional results following robot-assisted radical prostatectomy* App for prostate cancer(2020) FARIA, Leandro F.; REIS, Sabrina T.; LEITE, Katia R.; CRUZ, Jose Arnaldo Shiomi da; PIMENTA, Ruan; I, Nayara Viana; AMARAL, Gabriela Q.; SANTOS, Gabriel A. G. D.; ILIAS, Daniel; FAKHOURI, Felipe; XAVIER, Geraldo; SROUGI, Miguel; PASSEROTTI, Carlo CamargoIntroduction: Mobile applications (""apps"") developed for smartphones and tablets are increasingly used in healthcare, allowing remote patient support or promoting self-health care. Prostate cancer (PC) screening allows for early-stage PC diagnosis, resulting in high rates of curative procedures such as radical prostatectomy. The main complications following surgery are urinary incontinence and erectile dysfunction. However, the exact numbers related to these morbidities are often missing due to brief interviews during consultations in the medical office. Therefore, the aim of this study was to create an app to determine whether response rates to preand post-surgical PC questionnaires will increase. Methods: The app was built using the IONIC framework system and provided to patients through a prospective randomized study. We included 100 patients divided into two groups: 1. first group used the app (n = 50); and 2. second group responded via validated printed questionnaires (control group) (n = 50). All patients received discharge counseling to respond to the questionnaires 1, 3, 6 and 12 months after the procedure. The app group received verbal guidance on how monitoring would occur, received an SMS containing a username and password providing access to the system and received reminder alerts to respond to the questionnaires. Results: The new app is called UroHealth and is available for download in the Apple App Store or at www.urohealth.com.br . When we evaluated the response rates, we found that 42.9% of the patients answered the preoperative questionnaire in the app group, while 16% responded in the control group (p = 0.003). By the end of the follow-up, we found that 24.5% of the patients answered the questionnaire in the app group, while 4% responded in the control group (p = 0.003). Conclusion: This app enabled almost 6 times more patients to answer long-term follow-up questions after surgical procedures, providing high-quality information regarding morbidity related to treatment. Although our initial results indicate that this app may become a useful tool in obtaining more frequent and realistic answers, thus helping to improve surgical techniques, other ways of reaching the patient should be tested to achieve higher response rates.
- HPV Genotype Prevalence and Success of Vaccination to Prevent Cervical Cancer(2020) LEITE, Katia Ramos Moreira; PIMENTA, Ruan; CANAVEZ, Juliana; CANAVEZ, Flavio; SOUZA, Fernando R. de; VARA, Ligia; ESTIVALLET, Carmen; CAMARA-LOPES, Luiz HeraldoBackground:Nearly 500,000 new cases of cervical cancer are estimated annually worldwide. Three vaccines are currently licensed to prevent cervical cancer. The success of vaccination depends mainly on the prevalence of HPV genotypes, and many cases of HPV infection have been diagnosed after vaccination. Our aim was to search for HPV genotyping in cervical samples to verify the proportion of women that remain susceptible to infection even after vaccination.Methods:21,017 liquid-based cervical (LBC) specimens were received for cytology and HPV detection from 2015 to 2018. Before slide preparations for cytology, a 1,000-mu L aliquot was taken from the LBC fixative and subjected to automated DNA extraction and multiplex PCR followed by capillary electrophoresis to detect and classify HPV.Results:HPV was detected in 895 (4.3%) specimens. The most prevalent genotype was HPV-16, followed by HPV-58 and HPV-66. A total of 258 (28.8%) cases were positive for high-risk (HR)-HPV types (66, 59, 39, 56, 30, 35, 53, 51, 68, 82, and 70) that are not covered by the HPV vaccines.Conclusion:A significant proportion of HPV types detected in cytological specimens are representative of HR-HPV not covered by the available vaccines. The health system should be aware of the considerable percentage of women who are not being immunized and will continue to need cervical cancer screening.